Ann: Quarterly Review, page-16

Ehh are waiting on approval from drug administration, that is what is holding up sales.
Eagle Health continued with the registration of the Hutang‐1 product formula with the China Food & Drug Administration (CFDA) as a Food for Special Medical Purpose (FSMP). Eagle Health expects the FSMP registration process to be completed by Q4 2019. In the meantime, product sales have been restricted until this is granted. Due to the lack of sales in the period, Eagle Health did not meet the sales target required to maintain exclusivity in the Chinese market. Consequently, the Eagle Health licence for the Chinese market has reverted to a non‐exclusive licence.